Business Wire

ABB and Kawasaki Announce Collaborative Robot Automation Cooperation

Jaa

ABB and Kawasaki Heavy Industries, two global industrial automation and robot suppliers, announced today that the companies will join forces to share knowledge and promote the benefits of collaborative robots, in particular those with dual arm designs. The global cooperation will become effective immediately.

Under the new cooperation, which is the world’s first to focus on ‘cobots,’ both robot makers will continue independently manufacturing and marketing their own offerings while working together on joint technical and awareness opportunities. This includes educating policy makers, NGOs and the general public about the benefits of collaborative automation, and creating common industry approaches to safety, programming and communications.

Collaboration between people and robots, machines and processes is increasingly important as production in many industries has shifted from larger lots with little variation to low volumes with a high mix. This means more variability and more human intervention. Collaborative automation allows people and robots to each contribute their unique strengths – people offer process knowledge, insight and improvisation for change, while robots offer tireless endurance for repetitive tasks.

The cooperation also represents collaboration across borders, with ABB as Europe’s largest robot supplier and Kawasaki one of Asia’s industrial giants. “The scale and pace of change in the robotics industry today is unimaginable,” said Per Vegard Nerseth, Managing Director of ABB’s Robotics business. “Beyond the technologies behind collaborative automation, there is also a need for innovative new ways of working together and creating common industry approaches to safety, programming and communications.”

“Collaborative robots, especially those with two arms capable of human interactions, can greatly contribute to society and help the world cope with labor shortages and an aging workforce. We see high potential in expanding collaborative applications and processes where people and technology work together to create solutions,” said Yasuhiko Hashimoto, Managing Executive Officer and General Manager, Kawasaki Robot Division. “I’m very pleased that ABB and Kawasaki are joining forces to lead the drive for more user-friendly, advanced collaborative automation.”

ABB is recognized as a pioneer in collaborative automation through its YuMi dual arm robot, the world’s first truly collaborative robot. The YuMi robot makes it possible for people and robots to safely share common tasks such as assembling small electronics.

Kawasaki is offering a very unique and innovative Dual-Arm SCARA Robot “duAro”, which has been developed based on extensive application know-how and which can safely collaborate with humans in the workplace.

The first output from this cooperation will be a collaborative dual arm robot demonstration in Booth IR3-56, IR5-22 and SR-82 at IREX, to be held in Tokyo, Japan from November 29 to December 2, 2017.

ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing a more than 125-year history of innovation, ABB today is writing the future of industrial digitalization and driving the Energy and Fourth Industrial Revolutions. ABB operates in more than 100 countries with about 136,000 employees. www.abb.com

ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, we are active in 53 countries and over 100 locations and have shipped over 300,000 robot solutions in a diverse range of industries and applications. We help our customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics

Kawasaki was founded more than 120 years ago and has been developing globally while producing revolutionary products by working together to ensure technology synergies across its different divisions.

Kawasaki is now recognized as a global leader in diverse industries in wide ranging fields going beyond land, sea and air, offering state-of-the-art technologies for environmental and energy infrastructure, machinery and robotics, and various types of transportation in marine, railway and aerospace to a leisure vehicles as motorcycles and personal watercraft in global basis with about 35,200 employees. global.kawasaki.com

Kawasaki Robotics is a leading supplier of industrial robots and robot automation systems with a broad product portfolio having shipped 170,000 robots in about 50 countries. As a pioneer in Japan, Kawasaki celebrates its 50th anniversary in 2017. As one of the world’s leading robotics suppliers, we are now transforming ourselves from an industrial to a fully integrated robot supplier. Kawasaki is a solution provider having deep application know-how through diverse business and products on land, sea and air. robotics.kawasaki.com

Contact information

ABB Media Relations
+41 43 317 71 11
media.relations@ch.abb.com
or
ABB Investor Relations
+41 43 317 71 11
investor.relations@ch.abb.com
or
Kawasaki Media Relations
webadmin@khi.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00Tiedote

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo

Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific Antibody HEMLIBRA® at WFH 201821.5.2018 12:44Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that full results from HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160) evaluating Chugai’s hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] are being presented at the World Federation of Hemophilia 2018 World Congress held in Glasgow, Scotland from May 20 to 24. HAVEN 3 study is conducted in people with hemophilia A without inhibitors, and HAVEN 4 study is conducted in people with hemophilia A with or without inhibitors. Results from both studies will be presented as late-breaking abstracts. “The results from HAVEN 3 study demonstrate that HEMLIBRA, which was created with Chugai’s proprietary antibody engineering technologies, can reduce the bleeding risk in people with hemophilia A without inhibitors. The intra-patient comparison in this study also shows a statistically significant reduction in bleeding by HEMLIBRA prophylaxis compared to factor VIII therapy, the current stand

STATS Unveils STATS GPS, the Most Advanced Technology for Athlete Monitoring21.5.2018 10:00Tiedote

Today, STATS, the worldwide leader in sports data and intelligence, unveiled STATS GPS, an innovative system that uses a revolutionary 50-Hz sampling frequency to provide the most advanced real-time GPS technology available. STATS GPS allows teams to monitor player performance with customizable metrics like accelerations/decelerations, energy expenditure, count of zone entries, and time, distance and power thresholds. The innovative solution uses real 50-Hz sampling frequency and allows practitioners to monitor up to 100 players in real-time and post session with over 300 GPS, IMU and HR derived metrics. Embedded in the GPS vests are textile heart-rate sensors, making STATS GPS the most advanced technology on the market. “Teams and conditioning coaches need the latest technology to ensure players stay at peak health and fitness during long seasons,” said Ryan Paterson, Chief Global Officer at STATS. “With STATS GPS’ new 50-Hz technology, teams can instantly get performance information,

Sofinnova Partners Appoints Dr. Martin T. Rothman as Venture Partner21.5.2018 09:00Tiedote

Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Dr. Martin T. Rothman as Venture Partner. Dr. Rothman brings forty years of experience and a strong international network in the medical field to Sofinnova Partners. As Venture Partner, Dr. Rothman will focus on helping the team identify and evaluate promising medical device companies and on mentoring entrepreneurs and physicians launching clinical innovations. Sofinnova Partners and Dr. Rothman have closely collaborated over many years. Dr. Rothman is the founder of LimFlow and an independent board member of HighLife, both portfolio companies of Sofinnova Partners. Until recently, he was Vice President of medical affairs for coronary, structural heart and renal denervation for Medtronic, based in Santa Rosa (CA), a position he held since 2010. He was involved in the development of the renal denervation program, the Trans-Aortic Valve Replacement program, and the Medtronic percutaneo

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme